Guo-Qiang Chen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9544179/publications.pdf

Version: 2024-02-01

205 papers

18,624 citations

52 h-index 132

g-index

211 all docs

211 docs citations

times ranked

211

32610 citing authors

#	Article	IF	CITATIONS
1	Epithelial cells-enriched IncRNA SNHG8 regulates chromatin condensation by binding to Histone H1s. Cell Death and Differentiation, 2022, 29, 1569-1581.	11.2	8
2	<i>Lacticaseibacillus paracasei sh2020</i> induced antitumor immunity and synergized with anti-programmed cell death 1 to reduce tumor burden in mice. Gut Microbes, 2022, 14, 2046246.	9.8	27
3	MUC1 triggers lineage plasticity of Her2 positive mammary tumors. Oncogene, 2022, 41, 3064-3078.	5.9	5
4	The phosphatase PTEN links platelets with immune regulatory functions of mouse T follicular helper cells. Nature Communications, 2022, 13, 2762.	12.8	7
5	Furin extracellularly cleaves secreted PTENÎ \pm /Î 2 to generate C-terminal fragment with a tumor-suppressive role. Cell Death and Disease, 2022, 13, .	6.3	4
6	FAM122A is required for hematopoietic stem cell function. Leukemia, 2021, 35, 2130-2134.	7.2	3
7	FAM122A promotes acute myeloid leukemia cell growth through inhibiting PP2A activity and sustaining MYC expression. Haematologica, 2021, 106, 903-907.	3.5	4
8	Loss of IncRNA SNHG8 promotes epithelial-mesenchymal transition by destabilizing CDH1 mRNA. Science China Life Sciences, 2021, 64, 1858-1867.	4.9	5
9	Reply to: Binding site for MDL-801 on SIRT6. Nature Chemical Biology, 2021, 17, 522-523.	8.0	9
10	Glucose limitation activates AMPK coupled SENP1-Sirt3 signalling in mitochondria for T cell memory development. Nature Communications, 2021, 12, 4371.	12.8	55
11	ANP32B-mediated repression of p53 contributes to maintenance of normal and CML stem cells. Blood, 2021, 138, 2485-2498.	1.4	9
12	KAT6A Acetylation of SMAD3 Regulates Myeloidâ€Derived Suppressor Cell Recruitment, Metastasis, and Immunotherapy in Tripleâ€Negative Breast Cancer. Advanced Science, 2021, 8, e2100014.	11.2	30
13	WWP1 targeting MUC1 for ubiquitin-mediated lysosomal degradation to suppress carcinogenesis. Signal Transduction and Targeted Therapy, 2021, 6, 297.	17.1	7
14	Hypoxia regulates overall mRNA homeostasis by inducing Met1-linked linear ubiquitination of AGO2 in cancer cells. Nature Communications, 2021, 12, 5416.	12.8	23
15	Targeting USP47 overcomes tyrosine kinase inhibitor resistance and eradicates leukemia stem/progenitor cells in chronic myelogenous leukemia. Nature Communications, 2021, 12, 51.	12.8	34
16	Unraveling allosteric landscapes of allosterome with ASD. Nucleic Acids Research, 2020, 48, D394-D401.	14.5	29
17	FAM122A supports the growth of hepatocellular carcinoma cells and its deletion enhances Doxorubicin-induced cytotoxicity. Experimental Cell Research, 2020, 387, 111714.	2.6	9
18	FAM122A Inhibits Erythroid Differentiation through GATA1. Stem Cell Reports, 2020, 15, 721-734.	4.8	2

#	Article	IF	Citations
19	FAM122A maintains DNA stability possibly through the regulation of topoisomerase IIα expression. Experimental Cell Research, 2020, 396, 112242.	2.6	2
20	MDH1-mediated malate-aspartate NADH shuttle maintains the activity levels of fetal liver hematopoietic stem cells. Blood, 2020, 136, 553-571.	1.4	13
21	P53 suppresses SENP3 phosphorylation to mediate G2 checkpoint. Cell Discovery, 2020, 6, 21.	6.7	15
22	FBXO22 degrades nuclear PTEN to promote tumorigenesis. Nature Communications, 2020, 11, 1720.	12.8	49
23	Biomimetic, Hypoxiaâ€Responsive Nanoparticles Overcome Residual Chemoresistant Leukemic Cells with Coâ€Targeting of Therapyâ€Induced Bone Marrow Niches. Advanced Functional Materials, 2020, 30, 2000309.	14.9	29
24	A tentative discussion of medical education and cultures of science. Cultures of Science, 2020, 3, 227-231.	0.8	0
25	2-Bromopalmitate targets retinoic acid receptor alpha and overcomes all-trans retinoic acid resistance of acute promyelocytic leukemia. Haematologica, 2019, 104, 102-112.	3.5	10
26	SENP1-Sirt3 Signaling Controls Mitochondrial Protein Acetylation and Metabolism. Molecular Cell, 2019, 75, 823-834.e5.	9.7	119
27	SUMO-Specific Protease 1 Is Critical for Myeloid-Derived Suppressor Cell Development and Function. Cancer Research, 2019, 79, 3891-3902.	0.9	12
28	AlloDriver: a method for the identification and analysis of cancer driver targets. Nucleic Acids Research, 2019, 47, W315-W321.	14.5	31
29	Erlotinib overcomes paclitaxel-resistant cancer stem cells by blocking the EGFR-CREB/GR \hat{I}^2 -IL-6 axis in MUC1-positive cervical cancer. Oncogenesis, 2019, 8, 70.	4.9	33
30	PTENÎ \pm and PTENÎ 2 promote carcinogenesis through WDR5 and H3K4 trimethylation. Nature Cell Biology, 2019, 21, 1436-1448.	10.3	44
31	Metabolic Imaging Reveals a Unique Preference of Symmetric Cell Division and Homing of Leukemia-Initiating Cells in an Endosteal Niche. Cell Metabolism, 2019, 29, 950-965.e6.	16.2	49
32	Phenotype and target-based chemical biology investigations in cancers. National Science Review, 2019, 6, 1111-1127.	9.5	7
33	Mitotic Phosphorylation of SENP3 Regulates DeSUMOylation of Chromosome-Associated Proteins and Chromosome Stability. Cancer Research, 2018, 78, 2171-2178.	0.9	22
34	SUMOylation of the m6A-RNA methyltransferase METTL3 modulates its function. Nucleic Acids Research, 2018, 46, 5195-5208.	14.5	210
35	Identifying the SUMO1 modification of FAM122A leading to the degradation of PP2A-Cl $$ t by ubiquitin-proteasome system. Biochemical and Biophysical Research Communications, 2018, 500, 676-681.	2.1	4
36	<i>ent</i> -Jungermannenone C Triggers Reactive Oxygen Species-Dependent Cell Differentiation in Leukemia Cells. Journal of Natural Products, 2018, 81, 298-306.	3.0	7

#	Article	IF	CITATIONS
37	PPM1K Regulates Hematopoiesis and Leukemogenesis through CDC20-Mediated Ubiquitination of MEIS1 and p21. Cell Reports, 2018, 23, 1461-1475.	6.4	46
38	MicroRNA-494 inhibits breast cancer progression by directly targeting PAK1. Cell Death and Disease, 2018, 8, e2529-e2529.	6.3	72
39	MicroRNA-630 inhibits breast cancer progression by directly targeting BMI1. Experimental Cell Research, 2018, 362, 378-385.	2.6	17
40	Sin1 (Stress-Activated Protein Kinase-Interacting Protein) Regulates Ischemia-Induced Microthrombosis Through Integrin \hat{I} ±IIb \hat{I} 23-Mediated Outside-In Signaling and Hypoxia Responses in Platelets. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 2793-2805.	2.4	15
41	JAM3 maintains leukemia-initiating cell self-renewal through LRP5/AKT/β-catenin/CCND1 signaling. Journal of Clinical Investigation, 2018, 128, 1737-1751.	8.2	40
42	LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration. Nature, 2018, 562, 605-609.	27.8	172
43	Identification of a cellularly active SIRT6 allosteric activator. Nature Chemical Biology, 2018, 14, 1118-1126.	8.0	193
44	MiR-133b targets Sox9 to control pathogenesis and metastasis of breast cancer. Cell Death and Disease, 2018, 9, 752.	6.3	63
45	Vacuolar Protein Sorting 33B Is a Tumor Suppressor in Hepatocarcinogenesis. Hepatology, 2018, 68, 2239-2253.	7.3	37
46	AlloFinder: a strategy for allosteric modulator discovery and allosterome analyses. Nucleic Acids Research, 2018, 46, W451-W458.	14.5	79
47	Leukaemic alterations of IKZF1 prime stemness and malignancy programs in human lymphocytes. Cell Death and Disease, 2018, 9, 526.	6.3	6
48	Nuclear PTEN safeguards pre-mRNA splicing to link Golgi apparatus for its tumor suppressive role. Nature Communications, 2018, 9, 2392.	12.8	47
49	MUC1 induces M2 type macrophage influx during postpartum mammary gland involution and triggers breast cancer. Oncotarget, 2018, 9, 3446-3458.	1.8	6
50	CD244 maintains the proliferation ability of leukemia initiating cells through SHP-2/p27 ^{kip1} signaling. Haematologica, 2017, 102, 707-718.	3.5	23
51	VHL deficiency augments anthracycline sensitivity of clear cell renal cell carcinomas by down-regulating ALDH2. Nature Communications, 2017, 8, 15337.	12.8	43
52	Proteome-Scale Investigation of Protein Allosteric Regulation Perturbed by Somatic Mutations in 7,000 Cancer Genomes. American Journal of Human Genetics, 2017, 100, 5-20.	6.2	72
53	Peptidomimetic inhibitors of APC–Asef interaction block colorectal cancer migration. Nature Chemical Biology, 2017, 13, 994-1001.	8.0	79
54	DNMT1-maintained hypermethylation of Krüppel-like factor 5 involves in the progression of clear cell renal cell carcinoma. Cell Death and Disease, 2017, 8, e2952-e2952.	6.3	21

#	Article	IF	Citations
55	MUC1 induces acquired chemoresistance by upregulating ABCB1 in EGFR-dependent manner. Cell Death and Disease, 2017, 8, e2980-e2980.	6.3	61
56	Pyruvate kinase M2 phosphorylates H2AX and promotes genomic instability in human tumor cells. Oncotarget, 2017, 8, 109120-109134.	1.8	22
57	APC/C is essential for hematopoiesis and impaired in aplastic anemia. Oncotarget, 2017, 8, 63360-63369.	1.8	2
58	Sorting protein VPS33B regulates exosomal autocrine signaling to mediate hematopoiesis and leukemogenesis. Journal of Clinical Investigation, 2016, 126, 4537-4553.	8.2	72
59	Vps33b regulates Vwfâ€positive vesicular trafficking in megakaryocytes. Journal of Pathology, 2016, 240, 108-119.	4.5	34
60	Molecular Mechanism of Z $\hat{l}\pm 1$ -Antitrypsin Deficiency. Journal of Biological Chemistry, 2016, 291, 15674-15686.	3.4	30
61	Downregulation of AIF by HIF-1 contributes to hypoxia-induced epithelial–mesenchymal transition of colon cancer. Carcinogenesis, 2016, 37, 1079-1088.	2.8	21
62	CD274 promotes cell cycle entry of leukemia-initiating cells through JNK/Cyclin D2 signaling. Journal of Hematology and Oncology, 2016, 9, 124.	17.0	20
63	A Novel Role for Pyruvate Kinase M2 as a Corepressor for P53 during the DNA Damage Response in Human Tumor Cells. Journal of Biological Chemistry, 2016, 291, 26138-26150.	3.4	29
64	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
65	ASD v3.0: unraveling allosteric regulation with structural mechanisms and biological networks. Nucleic Acids Research, 2016, 44, D527-D535.	14.5	116
66	Inhibition of Snail Family Transcriptional Repressor 2 (SNAI2) Enhances Multidrug Resistance of Hepatocellular Carcinoma Cells. PLoS ONE, 2016, 11, e0164752.	2.5	10
67	FAM122A, a new endogenous inhibitor of protein phosphatase 2A. Oncotarget, 2016, 7, 63887-63900.	1.8	26
68	MiR-630 suppresses breast cancer progression by targeting metadherin. Oncotarget, 2016, 7, 1288-1299.	1.8	46
69	<scp>AIF</scp> inhibits tumor metastasis by protecting <scp>PTEN</scp> from oxidation. EMBO Reports, 2015, 16, 1563-1580.	4.5	41
70	ANGPTL2/LILRB2 signaling promotes the propagation of lung cancer cells. Oncotarget, 2015, 6, 21004-21015.	1.8	50
71	Characterization of Sin1 Isoforms Reveals an mTOR-Dependent and Independent Function of Sin1 \hat{i}^3 . PLoS ONE, 2015, 10, e0135017.	2.5	24
72	Oridonin stabilizes retinoic acid receptor alpha through ROS-activated NF-lºB signaling. BMC Cancer, 2015, 15, 248.	2.6	21

#	Article	IF	Citations
73	Natural products against hematological malignancies and identification of their targets. Science China Life Sciences, 2015, 58, 1191-1201.	4.9	8
74	Cbx4 Governs HIF- $1\hat{1}$ to Potentiate Angiogenesis of Hepatocellular Carcinoma by Its SUMO E3 Ligase Activity. Cancer Cell, 2014, 25, 547-548.	16.8	2
75	ASD v2.0: updated content and novel features focusing on allosteric regulation. Nucleic Acids Research, 2014, 42, D510-D516.	14.5	96
76	Cbx4 Governs HIF- $1\hat{l}\pm$ to Potentiate Angiogenesis of Hepatocellular Carcinoma by Its SUMO E3 Ligase Activity. Cancer Cell, 2014, 25, 118-131.	16.8	180
77	Important Role of SUMOylation of Spliceosome Factors in Prostate Cancer Cells. Journal of Proteome Research, 2014, 13, 3571-3582.	3.7	60
78	Polycomb chromobox 4 enhances migration and pulmonary metastasis of hepatocellular carcinoma cell line MHCC97L. Science China Life Sciences, 2014, 57, 610-617.	4.9	15
79	Sumoylation of hypoxia inducible factor- $\hat{1}$ and its significance in cancer. Science China Life Sciences, 2014, 57, 657-664.	4.9	19
80	Leukemia Propagating Cells Rebuild an Evolving Niche in Response to Therapy. Cancer Cell, 2014, 25, 778-793.	16.8	169
81	Profilin 1 is essential for retention and metabolism of mouse hematopoietic stem cells in bone marrow. Blood, 2014, 123, 992-1001.	1.4	40
82	Paired immunoglobulin-like receptor B regulates platelet activation. Blood, 2014, 124, 2421-2430.	1.4	42
83	Microtubule-Associated Protein 1 Light Chain 3 Interacts with and Contributes to Growth Inhibiting Effect of PML. PLoS ONE, 2014, 9, e113089.	2.5	13
84	Phosphoproteomics Study on the Activated PKCÎ'-Induced Cell Death. Journal of Proteome Research, 2013, 12, 4280-4301.	3.7	8
85	PKCÎ' enhances C/EBPα degradation via inducing its phosphorylation and cytoplasmic translocation. Biochemical and Biophysical Research Communications, 2013, 433, 220-225.	2.1	5
86	Targeting peroxiredoxins against leukemia. Experimental Cell Research, 2013, 319, 170-176.	2.6	26
87	Hypoxia-inducible factor 1α mediates the down-regulation of superoxide dismutase 2 in von Hippel–Lindau deficient renal clear cell carcinoma. Biochemical and Biophysical Research Communications, 2013, 435, 46-51.	2.1	31
88	MiR-124 targets Slug to regulate epithelial–mesenchymal transition and metastasis of breast cancer. Carcinogenesis, 2013, 34, 713-722.	2.8	176
89	Metallopanstimulin-1 regulates invasion and migration of gastric cancer cells partially through integrin \hat{l}^2 4. Carcinogenesis, 2013, 34, 2851-2860.	2.8	35
90	Preventive and Therapeutic Effects of Adenanthin on Experimental Autoimmune Encephalomyelitis by Inhibiting NF-κB Signaling. Journal of Immunology, 2013, 191, 2115-2125.	0.8	20

#	Article	lF	CITATIONS
91	Fev regulates hematopoietic stem cell development via ERK signaling. Blood, 2013, 122, 367-375.	1.4	48
92	PLZF Mediates the PTEN/AKT/FOXO3a Signaling in Suppression of Prostate Tumorigenesis. PLoS ONE, 2013, 8, e77922.	2.5	34
93	Oridonin Upregulates All-Trans Retinoic Acid Receptor Alpha and Induces Differentiation Of NB4 Cells Though NF-Kb Pathway. Blood, 2013, 122, 2909-2909.	1.4	1
94	19-Oxygenatedent-Kaurane Diterpenoids fromIsodon pharicus. Planta Medica, 2012, 78, 52-58.	1.3	6
95	Receptor-transporting Protein 1 Short (RTP1S) Mediates Translocation and Activation of Odorant Receptors by Acting through Multiple Steps. Journal of Biological Chemistry, 2012, 287, 22287-22294.	3.4	42
96	Crucial role of copper in detection of metal-coordinating odorants. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 3492-3497.	7.1	104
97	Protein Kinase Cδ in Apoptosis: A Brief Overview. Archivum Immunologiae Et Therapiae Experimentalis, 2012, 60, 361-372.	2.3	70
98	c-Abl promotes osteoblast expansion by differentially regulating canonical and non-canonical BMP pathways and p16INK4a expression. Nature Cell Biology, 2012, 14, 727-737.	10.3	49
99	Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544.	9.1	3,122
100	SUMO1 modification of PTEN regulates tumorigenesis by controlling its association with the plasma membrane. Nature Communications, 2012 , 3 , 911 .	12.8	160
101	Proteomic Identification of Common SCF Ubiquitin Ligase FBXO6-Interacting Glycoproteins in Three kinds of Cells. Journal of Proteome Research, 2012, 11, 1773-1781.	3.7	39
102	Dissecting cell death with proteomic scalpels. Proteomics, 2012, 12, 597-606.	2.2	4
103	Adenanthin targets peroxiredoxin I and II to induce differentiation of leukemic cells. Nature Chemical Biology, 2012, 8, 486-493.	8.0	176
104	Knockdown of metallopanstimulinâ€1 inhibits NFâ€îºB signaling at different levels: The role of apoptosis induction of gastric cancer cells. International Journal of Cancer, 2012, 130, 2761-2770.	5.1	31
105	Anticancer Effects of Intermittent Hypoxia in Acute Myeloid Leukemia., 2012,, 229-238.		0
106	Targeted genes and interacting proteins of hypoxia inducible factor-1. International Journal of Biochemistry and Molecular Biology, 2012, 3, 165-78.	0.1	138
107	Antiproliferative Diterpenoids from the Leaves of <i>lsodon rubescens </i> . Planta Medica, 2011, 77, 169-174.	1.3	12
108	Design, Synthesis, and Structureâ [^] Activity Relationship of <i>Trypanosoma brucei</i> Leucyl-tRNA Synthetase Inhibitors as Antitrypanosomal Agents. Journal of Medicinal Chemistry, 2011, 54, 1276-1287.	6.4	79

#	Article	IF	Citations
109	SUMO-specific protease 1 regulates the in vitro and in vivo growth of colon cancer cells with the upregulated expression of CDK inhibitors. Cancer Letters, 2011, 309, 78-84.	7.2	7 5
110	Ikaros is degraded by proteasome-dependent mechanism in the early phase of apoptosis induction. Biochemical and Biophysical Research Communications, 2011, 406, 430-434.	2.1	12
111	PU.1 directly regulates retinoic acid-induced expression of RIG-G in leukemia cells. FEBS Letters, 2011, 585, 375-380.	2.8	7
112	MicroRNA-26b is underexpressed in human breast cancer and induces cell apoptosis by targeting SLC7A11. FEBS Letters, 2011, 585, 1363-1367.	2.8	166
113	Apoptosis-inducing factor is a target gene of C/EBPα and participates in adipocyte differentiation. FEBS Letters, 2011, 585, 2307-2312.	2.8	9
114	Design, synthesis, and biological evaluation of benzodiazepine-based SUMO-specific protease 1 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 6389-6392.	2.2	43
115	Current advances in the application of proteomics in apoptosis research. Science China Life Sciences, 2011, 54, 209-219.	4.9	7
116	PML-RARÎ \pm enhances constitutive autophagic activity through inhibiting the Akt/mTOR pathway. Autophagy, 2011, 7, 1132-1144.	9.1	37
117	Pathologically decreased miR-26a antagonizes apoptosis and facilitates carcinogenesis by targeting MTDH and EZH2 in breast cancer. Carcinogenesis, 2011, 32, 2-9.	2.8	201
118	Synergistic Induction of Galectin-1 by CCAAT/Enhancer Binding Protein \hat{l}_{\pm} and Hypoxia-inducible Factor $1\hat{l}_{\pm}$ and Its Role in Differentiation of Acute Myeloid Leukemic Cells. Journal of Biological Chemistry, 2011, 286, 36808-36819.	3.4	48
119	ODORactor: a web server for deciphering olfactory coding. Bioinformatics, 2011, 27, 2302-2303.	4.1	30
120	Effector Caspases and Leukemia. International Journal of Cell Biology, 2011, 2011, 1-8.	2.5	20
121	Pharicin B stabilizes retinoic acid receptor- $\hat{l}\pm$ and presents synergistic differentiation induction with ATRA in myeloid leukemic cells. Blood, 2010, 116, 5289-5297.	1.4	46
122	PTEN regulates collagen-induced platelet activation. Blood, 2010, 116, 2579-2581.	1.4	63
123	Molecular mechanisms of leukemia-associated protein degradation. Frontiers of Medicine in China, 2010, 4, 363-370.	0.1	3
124	Synergistic mitosis-arresting effects of arsenic trioxide and paclitaxel on human malignant lymphocytes. Chemico-Biological Interactions, 2010, 183, 222-230.	4.0	16
125	Four New Nortriterpenoids from <i>Schisandra lancifolia</i> . Helvetica Chimica Acta, 2010, 93, 1975-1982.	1.6	15
126	Induction of SENP1 in Endothelial Cells Contributes to Hypoxia-driven VEGF Expression and Angiogenesis. Journal of Biological Chemistry, 2010, 285, 36682-36688.	3.4	69

#	Article	IF	Citations
127	Hypoxia inducible factor-1 mediates expression of galectin-1: the potential role in migration/invasion of colorectal cancer cells. Carcinogenesis, 2010, 31, 1367-1375.	2.8	123
128	Downregulation of ANP32B, a novel substrate of caspase-3, enhances caspase-3 activation and apoptosis induction in myeloid leukemic cells. Carcinogenesis, 2010, 31, 419-426.	2.8	51
129	Pharicin A, a novel natural ent-kaurene diterpenoid, induces mitotic arrest and mitotic catastrophe of cancer cells by interfering with BubR1 function. Cell Cycle, 2010, 9, 2969-2979.	2.6	34
130	MDM4 overexpression contributes to synoviocyte proliferation in patients with rheumatoid arthritis. Biochemical and Biophysical Research Communications, 2010, 401, 417-421.	2.1	10
131	Protein Kinase Cδ Stimulates Proteasome-Dependent Degradation of C/EBPα during Apoptosis Induction of Leukemic Cells. PLoS ONE, 2009, 4, e6552.	2.5	12
132	Synergistic Induction of Inflammation by Bacterial Products Lipopolysaccharide and fMLP: An Important Microbial Pathogenic Mechanism. Journal of Immunology, 2009, 182, 2518-2524.	0.8	24
133	Protein Kinase C-δmediates down-regulation of heterogeneous nuclear ribonucleoprotein K protein: involvement in apoptosis induction. Experimental Cell Research, 2009, 315, 3250-3258.	2.6	34
134	Inhibition of DNA methyltransferase induces G2 cell cycle arrest and apoptosis in human colorectal cancer cells <i>via</i> inhibition of JAK2/STAT3/STAT5 signalling. Journal of Cellular and Molecular Medicine, 2009, 13, 3668-3679.	3.6	43
135	Nuclear translocation of dihydrofolate reductase is not a pre-requisite for DNA damage induced apoptosis. Apoptosis: an International Journal on Programmed Cell Death, 2009, 14, 699-710.	4.9	6
136	Cytotoxic ent-kaurane diterpenoids from Isodon sinuolata. Phytochemistry, 2009, 70, 1462-1466.	2.9	23
137	Active compounds-based discoveries about the differentiation and apoptosis of leukemic cells. Science Bulletin, 2009, 54, 4094-4101.	1.7	2
138	NSC606985, a novel camptothecin analog, induces apoptosis and growth arrest in prostate tumor cells. Cancer Chemotherapy and Pharmacology, 2009, 63, 303-312.	2.3	16
139	Differential protein expression in heart in UTâ€B null mice with cardiac conduction defects. Proteomics, 2009, 9, 504-511.	2.2	13
140	NDRG1 is downâ€regulated in the early apoptotic event induced by camptothecin analogs: The potential role in proteolytic activation of PKCÎ′ and apoptosis. Proteomics, 2009, 9, 2064-2075.	2.2	19
141	Proteomicsâ€based identification of two novel direct targets of hypoxiaâ€inducible factorâ€1 and their potential roles in migration/invasion of cancer cells. Proteomics, 2009, 9, 3901-3912.	2.2	77
142	Modulated Tâ€complex protein 1 ζ and peptidylâ€prolyl <i>cisâ€trans</i> isomerase B are two novel indicators for evaluating lymph node metastasis in colorectal cancer: Evidence from proteomics and bioinformatics. Proteomics - Clinical Applications, 2009, 3, 1225-1235.	1.6	8
143	Schilancidilactones A and B: two novel tetranortriterpenoids with an unprecedented skeleton from Schisandra lancifolia. Tetrahedron Letters, 2009, 50, 5962-5964.	1.4	30
144	NDRG1 contributes to retinoic acid-induced differentiation of leukemic cells. Leukemia Research, 2009, 33, 1108-1113.	0.8	23

#	Article	IF	CITATIONS
145	mTOR Signaling Pathway Is a Target for the Treatment of Colorectal Cancer. Annals of Surgical Oncology, 2009, 16, 2617-2628.	1.5	114
146	Alterations of Mitochondrial Enzymes Contribute to Cardiac Hypertrophy before Hypertension Development in Spontaneously Hypertensive Rats. Journal of Proteome Research, 2009, 8, 2463-2475.	3.7	44
147	<i>ent</i> -Kaurane Diterpenoids from <i>Isodon pharicus</i> . Journal of Natural Products, 2009, 72, 988-993.	3.0	21
148	NSC606985 induces apoptosis, exerts synergistic effects with cisplatin, and inhibits hypoxia-stabilized HIF- $1\hat{1}$ ± protein in human ovarian cancer cells. Cancer Letters, 2009, 278, 139-144.	7.2	16
149	PU.1, a novel capase-3 substrate, partially contributes to chemotherapeutic agents-induced apoptosis in leukemic cells. Biochemical and Biophysical Research Communications, 2009, 382, 508-513.	2.1	14
150	Hypoxia-HIF-1α-C/EBPα/Runx1 signaling in leukemic cell differentiation. Pathophysiology, 2009, 16, 297-303.	2.2	19
151	<i>ent</i> -Kaurane Diterpenoids from <i>Isodon scoparius</i> . Journal of Natural Products, 2009, 72, 125-129.	3.0	16
152	基于å°å^†å活性åŒ−å•̂物的白血病细胞å^†åŒ−ä¸Žå‡‹äº¡ä¿¡å•æœºå^¶. Chinese Science Bulletin,	, 20 009 , 54	, 2⊉59-2765.
153	Synergistic Anti-Cancer Effects of Arsenic Trioxide and Paclitaxel On Human Malignant Lymphocytes Blood, 2009, 114, 4809-4809.	1.4	0
154	MicroRNA Expression Contributes to Hypoxia-Inducible Factor-1a-Induced Differentiation of Myeloid Leukemic Cells Blood, 2009, 114, 1007-1007.	1.4	0
155	Phosphorylation of \hat{l}^2 -actin by protein kinase C-delta in camptothecin analog-induced leukemic cell apoptosis. Acta Pharmacologica Sinica, 2008, 29, 135-142.	6.1	26
156	Coiled-coil domain of PML is essential for the aberrant dynamics of PML-RARα, resulting in sequestration and decreased mobility of SMRT. Biochemical and Biophysical Research Communications, 2008, 365, 258-265.	2.1	9
157	Hyper-phosphorylation of $\hat{l}\pm$ -enolase in hypertrophied left ventricle of spontaneously hypertensive rat. Biochemical and Biophysical Research Communications, 2008, 371, 804-809.	2.1	20
158	Accumulation of hypoxia-inducible factor- $1\hat{A}$ protein and its role in the differentiation of myeloid leukemic cells induced by all-trans retinoic acid. Haematologica, 2008, 93, 1480-1487.	3.5	26
159	Differential Protein Expression in Heart in UTâ€B Null Mice with Cardiac Conduction Defects. FASEB Journal, 2008, 22, 963.1.	0.5	0
160	Acidic Leucine-Rich Nuclear Phosphoprotein 32 Family Member B (ANP32B), a Novel Caspase-3 Substrate, Exerts Anti-Apoptotic Effects on Acute Myeloid Leukemic Cells Blood, 2008, 112, 1337-1337.	1.4	0
161	Synergistically Cooperation of Bortezomib and Arsenic Trioxide on Chronic Myelogenous Leukemia. Blood, 2008, 112, 4233-4233.	1.4	0
162	Aberrant Chromatin Remodeling by Retinoic Acid Receptor \hat{l}_{\pm} Fusion Proteins Assessed at the Single-Cell Level. Molecular Biology of the Cell, 2007, 18, 3941-3951.	2.1	15

#	Article	IF	Citations
163	c-Jun N-terminal kinase mediates AML1-ETO protein-induced connexin-43 expression. Biochemical and Biophysical Research Communications, 2007, 356, 505-511.	2.1	28
164	Effect of block deletions in the C-terminus on the functional expression of human anion exchanger 1 (AE1). Molecular Membrane Biology, 2007, 24, 65-73.	2.0	8
165	Subcellular Proteome Analysis of Camptothecin Analogue NSC606985-Treated Acute Myeloid Leukemic Cells. Journal of Proteome Research, 2007, 6, 3808-3818.	3.7	34
166	Expression of Anion Exchanger 1 Sequestrates p16 in the Cytoplasm in Gastric, Colonic Adenocarcinoma. Neoplasia, 2007, 9, 812-819.	5.3	45
167	Therapeutic efficacy of NSC606985, a novel camptothecin analog, in a mouse model of acute promyelocytic leukemia. Leukemia Research, 2007, 31, 1565-1574.	0.8	17
168	Leukemia, an effective model for chemical biology and target therapy. Acta Pharmacologica Sinica, 2007, 28, 1316-1324.	6.1	13
169	Leukemogenic AML1-ETO fusion protein increases carcinogen-DNA adduct formation with upregulated expression of cytochrome P450-1A1 gene. Experimental Hematology, 2007, 35, 1249-1255.	0.4	10
170	Proliferation and differentiation of bone marrow stromal cells under hypoxic conditions. Biochemical and Biophysical Research Communications, 2006, 347, 12-21.	2.1	194
171	Induction of tumor arrest and differentiation with prolonged survival by intermittent hypoxia in a mouse model of acute myeloid leukemia. Blood, 2006, 107, 698-707.	1.4	48
172	Differential protein expression in hypertrophic heart with and without hypertension in spontaneously hypertensive rats. Proteomics, 2006, 6, 1948-1956.	2.2	72
173	Comparative proteomic analysis of hypoxia-treated and untreated human leukemic U937 cells. Proteomics, 2006, 6, 3262-3274.	2.2	38
174	Anion exchanger 2 mediates the action of arsenic trioxide. British Journal of Haematology, 2006, 134, 491-499.	2.5	9
175	Hypoxia-mimetic agents desferrioxamine and cobalt chloride induce leukemic cell apoptosis through different hypoxia-inducible factor- $\hat{\Pi}$ ± independent mechanisms. Apoptosis: an International Journal on Programmed Cell Death, 2006, 11 , 67-77.	4.9	96
176	Leukemogenic AML1-ETO fusion protein upregulates expression of connexin 43: The role in AML1-ETO-induced growth arrest in leukemic cells. Journal of Cellular Physiology, 2006, 208, 594-601.	4.1	30
177	Immunodetection of human telomerase reverse-transcriptase (hTERT) re-appraised: nucleolin and telomerase cross paths. Journal of Cell Science, 2006, 119, 2797-2806.	2.0	112
178	RIG-G as a key mediator of the antiproliferative activity of interferon-related pathways through enhancing p21 and p27 proteins. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 16448-16453.	7.1	106
179	Hypoxia inducible factor-1alpha and leukemic cell differentiation. Acta Physiologica Sinica, 2006, 58, 5-13.	0.5	2
180	Comparative proteomic analysis of human leukemic cells with and without inducible expression of leukemogenic AML1-ETO protein. Chinese Journal of Physiology, 2006, 49, 182-91.	1.0	5

#	Article	IF	CITATIONS
181	Phospholipid scramblase 1. Acta Physiologica Sinica, 2006, 58, 501-10.	0.5	7
182	Nanomolar concentration of NSC606985, a camptothecin analog, induces leukemic-cell apoptosis through protein kinase Cl̂ –dependent mechanisms. Blood, 2005, 105, 3714-3721.	1.4	53
183	Detecting correlation between sequence and expression divergences in a comparative analysis of human serpin genes. BioSystems, 2005, 82, 226-234.	2.0	4
184	<i>AML1-ETO</i> and <i>C-KIT</i> mutation/overexpression in t(8;21) leukemia: Implication in stepwise leukemogenesis and response to Gleevec. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 1104-1109.	7.1	272
185	As2O3enhances the anion transport activity of band 3 and the action is related with the C-terminal 16 residues of the protein. Journal of Drug Targeting, 2005, 13, 235-243.	4.4	3
186	Interferon- \hat{l}_{\pm} -induced Expression of Phospholipid Scramblase 1 through STAT1 Requires the Sequential Activation of Protein Kinase Cδ and JNK. Journal of Biological Chemistry, 2005, 280, 42707-42714.	3.4	48
187	Prediction of Pancreatic Cancer by Serum Biomarkers Using Surface-Enhanced Laser Desorption/Ionization-Based Decision Tree Classification. Oncology, 2005, 68, 79-86.	1.9	85
188	Metavanadate suppresses desferrioxamine-induced leukemic cell differentiation with reduced hypoxia-inducible factor- $\hat{11}$ ± protein. Biochemical and Biophysical Research Communications, 2005, 332, 1140-1145.	2.1	10
189	Direct interaction and cooperative role of tumor suppressor p16 with band 3 (AE1). FEBS Letters, 2005, 579, 2105-2110.	2.8	22
190	Arsenic Trioxide and Leukemia., 2005,, 251-272.		O
190		3.5	0
	Arsenic Trioxide and Leukemia., 2005,, 251-272. Hypoxia-simulating agents and selective stimulation of arsenic trioxide-induced growth arrest and	3.5	
191	Arsenic Trioxide and Leukemia., 2005,, 251-272. Hypoxia-simulating agents and selective stimulation of arsenic trioxide-induced growth arrest and cell differentiation in acute promyelocytic leukemic cells. Haematologica, 2005, 90, 1607-16. Combined effects of As4S4 and imatinib on chronic myeloid leukemia cells and BCR-ABL oncoprotein.		16
191 192	Arsenic Trioxide and Leukemia. , 2005, , 251-272. Hypoxia-simulating agents and selective stimulation of arsenic trioxide-induced growth arrest and cell differentiation in acute promyelocytic leukemic cells. Haematologica, 2005, 90, 1607-16. Combined effects of As4S4 and imatinib on chronic myeloid leukemia cells and BCR-ABL oncoprotein. Blood, 2004, 104, 4219-4225. Protein kinase CÎ′ mediates retinoic acid and phorbol myristate acetate–induced phospholipid	1.4	16 73
191 192 193	Arsenic Trioxide and Leukemia., 2005,, 251-272. Hypoxia-simulating agents and selective stimulation of arsenic trioxide-induced growth arrest and cell differentiation in acute promyelocytic leukemic cells. Haematologica, 2005, 90, 1607-16. Combined effects of As4S4 and imatinib on chronic myeloid leukemia cells and BCR-ABL oncoprotein. Blood, 2004, 104, 4219-4225. Protein kinase CΠmediates retinoic acid and phorbol myristate acetate–induced phospholipid scramblase 1 gene expression: its role in leukemic cell differentiation. Blood, 2004, 104, 3731-3738. Methylated metabolites of arsenic trioxide are more potent than arsenic trioxide as apoptotic but not	1.4	16 73 94
191 192 193	Arsenic Trioxide and Leukemia. , 2005, , 251-272. Hypoxia-simulating agents and selective stimulation of arsenic trioxide-induced growth arrest and cell differentiation in acute promyelocytic leukemic cells. Haematologica, 2005, 90, 1607-16. Combined effects of As4S4 and imatinib on chronic myeloid leukemia cells and BCR-ABL oncoprotein. Blood, 2004, 104, 4219-4225. Protein kinase CΠmediates retinoic acid and phorbol myristate acetate–induced phospholipid scramblase 1 gene expression: its role in leukemic cell differentiation. Blood, 2004, 104, 3731-3738. Methylated metabolites of arsenic trioxide are more potent than arsenic trioxide as apoptotic but not differentiation inducers in leukemia and lymphoma cells. Cancer Research, 2003, 63, 1853-9. Treatment of Acute Promyelocytic Leukemia with ATRA and As ₂ O ₃ : A Model of Molecular. Cancer Biology and Therapy, 2002, 1, 614-620. Variant-type PML-RARÂ fusion transcript in acute promyelocytic leukemia: Use of a cryptic coding sequence from intron 2 of the RARÂ gene and identification of a new clinical subtype resistant to retinoic acid therapy. Proceedings of the National Academy of Sciences of the United States of	1.4	16 73 94 76
191 192 193 194	Arsenic Trioxide and Leukemia. , 2005, , 251-272. Hypoxia-simulating agents and selective stimulation of arsenic trioxide-induced growth arrest and cell differentiation in acute promyelocytic leukemic cells. Haematologica, 2005, 90, 1607-16. Combined effects of As4S4 and imatinib on chronic myeloid leukemia cells and BCR-ABL oncoprotein. Blood, 2004, 104, 4219-4225. Protein kinase CÎ' mediates retinoic acid and phorbol myristate acetateâ€"induced phospholipid scramblase 1 gene expression: its role in leukemic cell differentiation. Blood, 2004, 104, 3731-3738. Methylated metabolites of arsenic trioxide are more potent than arsenic trioxide as apoptotic but not differentiation inducers in leukemia and lymphoma cells. Cancer Research, 2003, 63, 1853-9. Treatment of Acute Promyelocytic Leukemia with ATRA and As ₂ O ₃ : A Model of Molecular. Cancer Biology and Therapy, 2002, 1, 614-620. Variant-type PML-RARÂ fusion transcript in acute promyelocytic leukemia: Use of a cryptic coding sequence from intron 2 of the RARÂ gene and identification of a new clinical subtype resistant to	1.4 1.4 0.9	16 73 94 76

#	Article	IF	CITATIONS
199	Arsenic trioxide, a therapeutic agent for APL. Oncogene, 2001, 20, 7146-7153.	5.9	207
200	Treatment of acute promyelocytic leukemia with arsenic compounds: In vitro and in vivo studies. Seminars in Hematology, 2001, 38, 26-36.	3.4	109
201	Treatment of Acute Promyelocytic Leukemia with Arsenic Trioxide: Clinical and Basic Studies. Leukemia and Lymphoma, 2001, 42, 1265-1273.	1.3	14
202	Studies on Treatment of Acute Promyelocytic Leukemia With Arsenic Trioxide: Remission Induction, Follow-Up, and Molecular Monitoring in 11 Newly Diagnosed and 47 Relapsed Acute Promyelocytic Leukemia Patients. Blood, 1999, 94, 3315-3324.	1.4	579
203	Apoptosis and Growth Inhibition in Malignant Lymphocytes After Treatment With Arsenic Trioxide at Clinically Achievable Concentrations. Journal of the National Cancer Institute, 1999, 91, 772-778.	6.3	271
204	Cellular and molecular mechanism of arsenic trioxide in the treatment of hematopoietic malignancies., 1999, 5, 82-88.		0
205	Use of Arsenic Trioxide (As2O3) in the Treatment of Acute Promyelocytic Leukemia (APL): II. Clinical Efficacy and Pharmacokinetics in Relapsed Patients. Blood, 1997, 89, 3354-3360.	1.4	1,316